SCOPUS 정보 검색 플랫폼

Volumn 181, Issue 3, 2012, Pages 1034-1043

Dual inhibition of met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer

(14) Takeuchi, Shinji a Wang, Wei a,b Li, Qi a,b Yamada, Tadaaki a Kita, Kenji a Donev, Ivan S a Nakamura, Takahiro a Matsumoto, Kunio a Shimizu, Eiji c Nishioka, Yasuhiko d Sone, Saburo d Nakagawa, Takayuki a,e Uenaka, Toshimitsu e Yano, Seiji a

a KANAZAWA UNIVERSITY (Japan)

b SOUTHERN MEDICAL UNIVERSITY (China)

c TOTTORI UNIVERSITY (Japan)

d UNIVERSITY OF TOKUSHIMA (Japan)

e EISAI CO LTD (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GOLVATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

AMINOPYRIDINES; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MICE; MODELS, BIOLOGICAL; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865240226 PISSN: 00029440 EISSN: 15252191 Source Type: Journal
DOI: 10.1016/j.ajpath.2012.05.023 Document Type: Article

Times cited : (60)

References (41)

1
- 52649131951
- Lung cancer
- R.S. Herbst, J.V. Heymach, S.M. Lippman Lung cancer N Engl J Med 359 2008 1367 1380
- (2008) N Engl J Med , vol.359 , pp. 1367-1380
- Herbst, R.S.¹ Heymach, J.V.² Lippman, S.M.³

2
- 2342471392
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
- T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
- (2004) N Engl J Med , vol.350 , pp. 2129-2139
- Lynch, T.J.¹ Bell, D.W.² Sordella, R.³ Gurubhagavatula, S.⁴ Okimoto, R.A.⁵ Brannigan, B.W.⁶ Harris, P.L.⁷ Haserlat, S.M.⁸ Supko, J.G.⁹ Haluska, F.G.¹⁰ Louis, D.N.¹¹ Christiani, D.C.¹² Settleman, J.¹³ Haber, D.A.¹⁴

3
- 2342624080
- EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
- J.G. Paez, P.A. Jnne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
- (2004) Science , vol.304 , pp. 1497-1500
- Paez, J.G.¹ Jnne, P.A.² Lee, J.C.³ Tracy, S.⁴ Greulich, H.⁵ Gabriel, S.⁶ Herman, P.⁷ Kaye, F.J.⁸ Lindeman, N.⁹ Boggon, T.J.¹⁰ Naoki, K.¹¹ Sasaki, H.¹² Fujii, Y.¹³ Eck, M.J.¹⁴ Sellers, W.R.¹⁵ Johnson, B.E.¹⁶ Meyerson, M.¹⁷

4
- 33845490014
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
- A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, D.H. Johnson Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
- (2006) N Engl J Med , vol.355 , pp. 2542-2550
- Sandler, A.¹ Gray, R.² Perry, M.C.³ Brahmer, J.⁴ Schiller, J.H.⁵ Dowlati, A.⁶ Lilenbaum, R.⁷ Johnson, D.H.⁸

5
- 75249087060
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
- T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M. Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
- (2010) Lancet Oncol , vol.11 , pp. 121-128
- Mitsudomi, T.¹ Morita, S.² Yatabe, Y.³ Negoro, S.⁴ Okamoto, I.⁵ Tsurutani, J.⁶ Seto, T.⁷ Satouchi, M.⁸ Tada, H.⁹ Hirashima, T.¹⁰ Asami, K.¹¹ Katakami, N.¹² Takada, M.¹³ Yoshioka, H.¹⁴ Shibata, K.¹⁵ Kudoh, S.¹⁶ Shimizu, E.¹⁷ Saito, H.¹⁸ Toyooka, S.¹⁹ Nakagawa, K.²⁰ Fukuoka, M.²¹ more..

6
- 77953930730
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
- M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita, T. Nukiwa Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
- (2010) N Engl J Med , vol.362 , pp. 2380-2388
- Maemondo, M.¹ Inoue, A.² Kobayashi, K.³ Sugawara, S.⁴ Oizumi, S.⁵ Isobe, H.⁶ Gemma, A.⁷ Harada, M.⁸ Yoshizawa, H.⁹ Kinoshita, I.¹⁰ Fujita, Y.¹¹ Okinaga, S.¹² Hirano, H.¹³ Yoshimori, K.¹⁴ Harada, T.¹⁵ Ogura, T.¹⁶ Ando, M.¹⁷ Miyazawa, H.¹⁸ Tanaka, T.¹⁹ Saijo, Y.²⁰ more..

7
- 74949110711
- Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
- D. Jackman, W. Pao, G.J. Riely, J.A. Engelman, M.G. Kris, P.A. Jnne, T. Lynch, B.E. Johnson, V.A. Miller Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28 2010 357 360
- (2010) J Clin Oncol , vol.28 , pp. 357-360
- Jackman, D.¹ Pao, W.² Riely, G.J.³ Engelman, J.A.⁴ Kris, M.G.⁵ Jnne, P.A.⁶ Lynch, T.⁷ Johnson, B.E.⁸ Miller, V.A.⁹

8
- 13844317894
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
- S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Jnne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, B. Halmos EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
- (2005) N Engl J Med , vol.352 , pp. 786-792
- Kobayashi, S.¹ Boggon, T.J.² Dayaram, T.³ Jnne, P.A.⁴ Kocher, O.⁵ Meyerson, M.⁶ Johnson, B.E.⁷ Eck, M.J.⁸ Tenen, D.G.⁹ Halmos, B.¹⁰

9
- 18244371651
- Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
- W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
- (2005) PLoS Med , vol.2 , pp. 73
- Pao, W.¹ Miller, V.A.² Politi, K.A.³ Riely, G.J.⁴ Somwar, R.⁵ Zakowski, M.F.⁶ Kris, M.G.⁷ Varmus, H.⁸

10
- 34249075147
- MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
- J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, P.A. Jnne MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
- (2007) Science , vol.316 , pp. 1039-1043
- Engelman, J.A.¹ Zejnullahu, K.² Mitsudomi, T.³ Song, Y.⁴ Hyland, C.⁵ Park, J.O.⁶ Lindeman, N.⁷ Gale, C.M.⁸ Zhao, X.⁹ Christensen, J.¹⁰ Kosaka, T.¹¹ Holmes, A.J.¹² Rogers, A.M.¹³ Cappuzzo, F.¹⁴ Mok, T.¹⁵ Lee, C.¹⁶ Johnson, B.E.¹⁷ Cantley, L.C.¹⁸ Jnne, P.A.¹⁹

11
- 56449089812
- Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations
- S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe, T. Nakamura, S. Sone Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations Cancer Res 68 2008 9479 9487
- (2008) Cancer Res , vol.68 , pp. 9479-9487
- Yano, S.¹ Wang, W.² Li, Q.³ Matsumoto, K.⁴ Sakurama, H.⁵ Nakamura, T.⁶ Ogino, H.⁷ Kakiuchi, S.⁸ Hanibuchi, M.⁹ Nishioka, Y.¹⁰ Uehara, H.¹¹ Mitsudomi, T.¹² Yatabe, Y.¹³ Nakamura, T.¹⁴ Sone, S.¹⁵

12
- 70350721786
- Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors
- W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, S. Yano Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors Clin Cancer Res 15 2009 6630 6638
- (2009) Clin Cancer Res , vol.15 , pp. 6630-6638
- Wang, W.¹ Li, Q.² Yamada, T.³ Matsumoto, K.⁴ Matsumoto, I.⁵ Oda, M.⁶ Watanabe, G.⁷ Kayano, Y.⁸ Nishioka, Y.⁹ Sone, S.¹⁰ Yano, S.¹¹

13
- 73649102105
- Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
- A.B. Turke, K. Zejnullahu, Y.L. Wu, Y. Song, D. Dias-Santagata, E. Lifshits, L. Toschi, A. Rogers, T. Mok, L. Sequist, N.I. Lindeman, C. Murphy, S. Akhavanfard, B.Y. Yeap, Y. Xiao, M. Capelletti, A.J. Iafrate, C. Lee, J.G. Christensen, J.A. Engelman, P.A. Jnne Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17 2010 77 88
- (2010) Cancer Cell , vol.17 , pp. 77-88
- Turke, A.B.¹ Zejnullahu, K.² Wu, Y.L.³ Song, Y.⁴ Dias-Santagata, D.⁵ Lifshits, E.⁶ Toschi, L.⁷ Rogers, A.⁸ Mok, T.⁹ Sequist, L.¹⁰ Lindeman, N.I.¹¹ Murphy, C.¹² Akhavanfard, S.¹³ Yeap, B.Y.¹⁴ Xiao, Y.¹⁵ Capelletti, M.¹⁶ Iafrate, A.J.¹⁷ Lee, C.¹⁸ Christensen, J.G.¹⁹ Engelman, J.A.²⁰ Jnne, P.A.²¹ more..

14
- 74949142595
- Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer
- T. Yamada, K. Matsumoto, W. Wang, Q. Li, Y. Nishioka, Y. Sekido, S. Sone, S. Yano Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer Clin Cancer Res 16 2010 174 183
- (2010) Clin Cancer Res , vol.16 , pp. 174-183
- Yamada, T.¹ Matsumoto, K.² Wang, W.³ Li, Q.⁴ Nishioka, Y.⁵ Sekido, Y.⁶ Sone, S.⁷ Yano, S.⁸

15
- 77950460014
- Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M. MET, and HGF status
- T. Onitsuka, H. Uramoto, N. Nose, M. Takenoyama, T. Hanagiri, K. Sugio, K. Yasumoto Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M. MET, and HGF status Lung Cancer 68 2010 198 203
- (2010) Lung Cancer , vol.68 , pp. 198-203
- Onitsuka, T.¹ Uramoto, H.² Nose, N.³ Takenoyama, M.⁴ Hanagiri, T.⁵ Sugio, K.⁶ Yasumoto, K.⁷

16
- 78650429490
- Phase IIb/III double-blind randomized trial of afatinib (BIBW2992, and irreversible inhibitor of EGFR/HER1 and Her2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 12 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1) (abstract LBA1)
- V.A. Miller, V. Hirsh, J. Cadranel, Y.-M. Chen, K. Park, S.W. Kim, Z. Caicun, M. Oberdick, M. Shahidi, C.H. Yang Phase IIb/III double-blind randomized trial of afatinib (BIBW2992, and irreversible inhibitor of EGFR/HER1 and Her2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 12 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1) (abstract LBA1) Ann Oncol 21 2010 viii1
- (2010) Ann Oncol , vol.21 , pp. 1
- Miller, V.A.¹ Hirsh, V.² Cadranel, J.³ Chen, Y.-M.⁴ Park, K.⁵ Kim, S.W.⁶ Caicun, Z.⁷ Oberdick, M.⁸ Shahidi, M.⁹ Yang, C.H.¹⁰

17
- 77954584507
- Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer
- L.V. Sequist, B. Besse, T.J. Lynch, V.A. Miller, K.K. Wong, B. Gitlitz, K. Eaton, C. Zacharchuk, A. Freyman, C. Powell, R. Ananthakrishnan, S. Quinn, J.C. Soria Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 3076 3083
- (2010) J Clin Oncol , vol.28 , pp. 3076-3083
- Sequist, L.V.¹ Besse, B.² Lynch, T.J.³ Miller, V.A.⁴ Wong, K.K.⁵ Gitlitz, B.⁶ Eaton, K.⁷ Zacharchuk, C.⁸ Freyman, A.⁹ Powell, C.¹⁰ Ananthakrishnan, R.¹¹ Quinn, S.¹² Soria, J.C.¹³

18
- 35548947467
- Inhibition of angiogenesis in the treatment of non-small cell lung cancer
- V.L. Keedy, A.B. Sandler Inhibition of angiogenesis in the treatment of non-small cell lung cancer Cancer Sci 98 2007 1825 1830
- (2007) Cancer Sci , vol.98 , pp. 1825-1830
- Keedy, V.L.¹ Sandler, A.B.²

19
- 4344694684
- Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor
- G. Dong, T.L. Lee, N.T. Yeh, J. Geoghegan, C.V. Waes, Z. Chen Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor Oncogene 23 2004 6199 6208
- (2004) Oncogene , vol.23 , pp. 6199-6208
- Dong, G.¹ Lee, T.L.² Yeh, N.T.³ Geoghegan, J.⁴ Waes, C.V.⁵ Chen, Z.⁶

20
- 0032477844
- Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis
- E. Van Belle, B. Witzenbichler, D. Chen, M. Silver, L. Chang, R. Schwall, J.M. Isner Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis Circulation 97 1998 381 390
- (1998) Circulation , vol.97 , pp. 381-390
- Van Belle, E.¹ Witzenbichler, B.² Chen, D.³ Silver, M.⁴ Chang, L.⁵ Schwall, R.⁶ Isner, J.M.⁷

21
- 71849098261
- E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
- T. Nakagawa, O. Tohyama, A. Yamaguchi, T. Matsushima, K. Takahashi, S. Funasaka, S. Shirotori, M. Asada, H. Obaishi E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models Cancer Sci 101 2010 210 215
- (2010) Cancer Sci , vol.101 , pp. 210-215
- Nakagawa, T.¹ Tohyama, O.² Yamaguchi, A.³ Matsushima, T.⁴ Takahashi, K.⁵ Funasaka, S.⁶ Shirotori, S.⁷ Asada, M.⁸ Obaishi, H.⁹

22
- 0025997879
- Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer
- N. Masuda, M. Fukuoka, K. Matsui, Y. Kusunoki, S. Kudoh, S. Negoro, N. Takifuji, M. Fujisue, H. Morino, K. Nakagawa, M. Nishioka, M. Takada Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer J Natl Cancer Inst 83 1991 1743 1748
- (1991) J Natl Cancer Inst , vol.83 , pp. 1743-1748
- Masuda, N.¹ Fukuoka, M.² Matsui, K.³ Kusunoki, Y.⁴ Kudoh, S.⁵ Negoro, S.⁶ Takifuji, N.⁷ Fujisue, M.⁸ Morino, H.⁹ Nakagawa, K.¹⁰ Nishioka, M.¹¹ Takada, M.¹²

23
- 33947224133
- Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
- T. Okabe, I. Okamoto, K. Tamura, M. Terashima, T. Yoshida, T. Satoh, M. Takada, M. Fukuoka, K. Nakagawa Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification Cancer Res 67 2007 2046 2053
- (2007) Cancer Res , vol.67 , pp. 2046-2053
- Okabe, T.¹ Okamoto, I.² Tamura, K.³ Terashima, M.⁴ Yoshida, T.⁵ Satoh, T.⁶ Takada, M.⁷ Fukuoka, M.⁸ Nakagawa, K.⁹

24
- 0025824738
- Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor
- R. Montesano, K. Matsumoto, T. Nakamura, L. Orci Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor Cell 67 1991 901 908
- (1991) Cell , vol.67 , pp. 901-908
- Montesano, R.¹ Matsumoto, K.² Nakamura, T.³ Orci, L.⁴

25
- 0021287698
- Rapid colorimetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokines
- L.M. Green, J.L. Reade, C.F. Ware Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines J Immunol Methods 70 1984 257 268
- (1984) J Immunol Methods , vol.70 , pp. 257-268
- Green, L.M.¹ Reade, J.L.² Ware, C.F.³

26
- 0030941377
- Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: The possibility of immunological overcoming of multidrug resistance
- Y. Nishioka, S. Yano, F. Fujiki, N. Mukaida, K. Matsushima, T. Tsuruo, S. Sone Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance Int J Cancer 71 1997 170 177
- (1997) Int J Cancer , vol.71 , pp. 170-177
- Nishioka, Y.¹ Yano, S.² Fujiki, F.³ Mukaida, N.⁴ Matsushima, K.⁵ Tsuruo, T.⁶ Sone, S.⁷

27
- 10744226251
- The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis
- C. Saucier, H. Khoury, K.M. Lai, P. Peschard, D. Dankort, M.A. Naujokas, J. Holash, G.D. Yancopoulos, W.J. Muller, T. Pawson, M. Park The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis Proc Natl Acad Sci U S A 101 2004 2345 2350
- (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 2345-2350
- Saucier, C.¹ Khoury, H.² Lai, K.M.³ Peschard, P.⁴ Dankort, D.⁵ Naujokas, M.A.⁶ Holash, J.⁷ Yancopoulos, G.D.⁸ Muller, W.J.⁹ Pawson, T.¹⁰ Park, M.¹¹

28
- 33745465488
- Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions
- K. Matsumoto, T. Nakamura Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions Int J Cancer 119 2006 477 483
- (2006) Int J Cancer , vol.119 , pp. 477-483
- Matsumoto, K.¹ Nakamura, T.²

29
- 42949138783
- HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells
- J.T. Chen, C.Y. Huang, Y.Y. Chiang, W.H. Chen, S.H. Chiou, C.Y. Chen, K.C. Chow HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells Am J Respir Cell Mol Biol 38 2008 559 565
- (2008) Am J Respir Cell Mol Biol , vol.38 , pp. 559-565
- Chen, J.T.¹ Huang, C.Y.² Chiang, Y.Y.³ Chen, W.H.⁴ Chiou, S.H.⁵ Chen, C.Y.⁶ Chow, K.C.⁷

30
- 0033806932
- Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression
- M. Hayashida, H. Kawano, T. Nakano, K. Shiraki, A. Suzuki Hepatocyte growth factor promotes cell survival from fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression Hepatology 32 2000 796 802
- (2000) Hepatology , vol.32 , pp. 796-802
- Hayashida, M.¹ Kawano, H.² Nakano, T.³ Shiraki, K.⁴ Suzuki, A.⁵

31
- 0346037266
- Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2: Implication in head and neck squamous cell carcinoma progression
- Q. Zeng, L.K. McCauley, C.Y. Wang Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2: implication in head and neck squamous cell carcinoma progression J Biol Chem 277 2002 50137 50142
- (2002) J Biol Chem , vol.277 , pp. 50137-50142
- Zeng, Q.¹ McCauley, L.K.² Wang, C.Y.³

32
- 78650339354
- HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
- F. Shojaei, J.H. Lee, B.H. Simmons, A. Wong, C.O. Esparza, P.A. Plumlee, J. Feng, A.E. Stewart, D.D. Hu-Lowe, J.G. Christensen HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors Cancer Res 70 2010 10090 10100
- (2010) Cancer Res , vol.70 , pp. 10090-10100
- Shojaei, F.¹ Lee, J.H.² Simmons, B.H.³ Wong, A.⁴ Esparza, C.O.⁵ Plumlee, P.A.⁶ Feng, J.⁷ Stewart, A.E.⁸ Hu-Lowe, D.D.⁹ Christensen, J.G.¹⁰

33
- 26644471951
- Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
- O. Casanovas, D.J. Hicklin, G. Bergers, D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
- (2005) Cancer Cell , vol.8 , pp. 299-309
- Casanovas, O.¹ Hicklin, D.J.² Bergers, G.³ Hanahan, D.⁴

34
- 0035925098
- Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects
- M. Hckel, P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276
- (2001) J Natl Cancer Inst , vol.93 , pp. 266-276
- Hckel, M.¹ Vaupel, P.²

35
- 0037478437
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
- S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, P.M. Comoglio Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
- (2003) Cancer Cell , vol.3 , pp. 347-361
- Pennacchietti, S.¹ Michieli, P.² Galluzzo, M.³ Mazzone, M.⁴ Giordano, S.⁵ Comoglio, P.M.⁶

36
- 0038376002
- Molecular regulation of vessel maturation
- R.K. Jain Molecular regulation of vessel maturation Nat Med 9 2003 685 693
- (2003) Nat Med , vol.9 , pp. 685-693
- Jain, R.K.¹

37
- 76749152925
- Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells
- S. Zhang, H.E. Zhau, A.O. Osunkoya, S. Iqbal, X. Yang, S. Fan, Z. Chen, R. Wang, F.F. Marshall, L.W. Chung, D. Wu Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells Mol Cancer 9 2010 9
- (2010) Mol Cancer , vol.9 , pp. 9
- Zhang, S.¹ Zhau, H.E.² Osunkoya, A.O.³ Iqbal, S.⁴ Yang, X.⁵ Fan, S.⁶ Chen, Z.⁷ Wang, R.⁸ Marshall, F.F.⁹ Chung, L.W.¹⁰ Wu, D.¹¹

38
- 35548962203
- Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
- T. Mitsudomi, Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824
- (2007) Cancer Sci , vol.98 , pp. 1817-1824
- Mitsudomi, T.¹ Yatabe, Y.²

39
- 77956654766
- Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma
- K. Kasahara, T. Arao, K. Sakai, K. Matsumoto, A. Sakai, H. Kimura, T. Sone, A. Horiike, M. Nishio, T. Ohira, N. Ikeda, T. Yamanaka, N. Saijo, K. Nishio Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma Clin Cancer Res 16 2010 4616 4624
- (2010) Clin Cancer Res , vol.16 , pp. 4616-4624
- Kasahara, K.¹ Arao, T.² Sakai, K.³ Matsumoto, K.⁴ Sakai, A.⁵ Kimura, H.⁶ Sone, T.⁷ Horiike, A.⁸ Nishio, M.⁹ Ohira, T.¹⁰ Ikeda, N.¹¹ Yamanaka, T.¹² Saijo, N.¹³ Nishio, K.¹⁴

40
- 79960914795
- Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs
- H. Tanaka, T. Kimura, S. Kudoh, S. Mitsuoka, T. Watanabe, T. Suzumura, K. Tachibana, M. Noguchi, S. Yano, K. Hirata Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs Int J Cancer 129 2011 1410 1416
- (2011) Int J Cancer , vol.129 , pp. 1410-1416
- Tanaka, H.¹ Kimura, T.² Kudoh, S.³ Mitsuoka, S.⁴ Watanabe, T.⁵ Suzumura, T.⁶ Tachibana, K.⁷ Noguchi, M.⁸ Yano, S.⁹ Hirata, K.¹⁰

41
- 80053627035
- Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer
- J.Y. Han, J.Y. Kim, S.H. Lee, N.J. Yoo, B.G. Choi Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer Lung Cancer 74 2011 293 299
- (2011) Lung Cancer , vol.74 , pp. 293-299
- Han, J.Y.¹ Kim, J.Y.² Lee, S.H.³ Yoo, N.J.⁴ Choi, B.G.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.